🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent paper in JACC Journals on screening yield in #HCM Important and useful data for physicians and patients jacc.org/doi/epdf/10.10…

Our latest NUDGE trial just published in JAMA 👇 Led by the brilliant Niklas Dyrby Johansen, in collaboration with amazing colleagues from Statens Serum Institut Harvard Medical School Region Midtjylland and many more. CTCPR Trials & CIRL continues to provide important evidence regarding how we can improve public health

Terrific work led by Josh Jacobs from AHA Science #GWTG_HF. 🔥#SimPub with #AHA24 now in Circ: Heart Failure Social Determinants of Health and Disparities in GDMT Optimization for Heart Failure ahajournals.org/doi/10.1161/CI… Gregg Fonarow MD Duke Clinical Research Institute AHA Research #GDMTworks

ICYMI: Catch up on HFSA Scientific Statement on Cardio-Oncology & HF in #JCF! 🔥 From HF in patients with cancer ➡️ cancer in patients with HF, this comprehensive review has you covered on all the latest in the Cardio-Oncology space. 🔗bit.ly/4dHwtnC

1/ New insights on blood pressure in HFmrEF/HFpEF! 🩺 A pooled analysis of 16,900+ patients shows a J-shaped relationship between SBP & cardiovascular risk. Let’s explore! 👇 JACC Journals #AHA24 jacc.org/doi/epdf/10.10…

Featured Science Sim Pub with #AHA24 from Pablo Martí & scottdavidsolomon et al published in Circ: Heart Failure: Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials Read more: ahajournals.org/doi/10.1161/CI… #AHAJournals Jon Cunningham

Adjudicating #HeartFailure in global trials is slow & costly. At #AHA24, we presented HF-NLP, an #AI model using #NLP to streamline this process. Our hybrid approach cuts workload by 84%, accelerating trials with high accuracy. Very excited for what's coming! #AHA2024

#PREVENTHF launching Mar '25 New large first-of-its-kind #CKM trial focused on *prevention* of HF n=11,300 pts w T2D, ASCVD, HTN (but w/o HF) Randomization: ASi (baxdrostat) + SGLT2i (dapagliflozin) vs SGLT2i alone PEP: new diagnosis of HF or CV death clinicaltrials.gov/study/NCT06677…

Thrilled to be part of the #PREVENTHF Steering Committee with an all-⭐️team. A novel trial moving from treatment➡️PREVENTION of #HF, a leading cause of morbidity/hosp/medical costs. Global launch: Mar'25 recruiting >11,000 pts scottdavidsolomon Muthu Vaduganathan CVCT - CardioVascular Clinical Trialists Tor Biering-Sørensen, MD, MSc, MPH, PhD

This. This is our future. Prevention 🤝 #FunctionNotFailure 🌎 Hoping to shift paradigms of care for our patients & eachother. >11000 pts at risk! Will SGLT2i & Aldo synthase inhibitor (ASi) prevent HF? Muthu Vaduganathan Maja Cikes Pam R. Taub, MD❤️💃🏻 Modele Ogunniyi, MD, MPH scottdavidsolomon

➡️Cagrilintide = long-acting amylin analog ➡️ Amylin = hormone secreted by pancreatic beta cells, along w/ insulin ➡️ binds to receptors in 🧠 to ⤴️ satiety & fullness, imp. in glucose reg. ➡️complementary to Glp1RA = Cagrisema More to learn. More to come. #FunctionNotFailure

Every organization/institution needs a defined identity - or an “elevator pitch” 🛗 (🙏🏽 Jeff Teuteberg) As we completed 4 years w/this ⭐️ team Journal of Cardiac Failure we’ve been thinking about this in our #SecondMountain (🙏🏽 Andrew J Sauer MD) The best is yet to come…💜 Our March Ed page

Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up. Full SOUL phase 3b trial

In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date) The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use #ACC25 ahajournals.org/doi/abs/10.116…

Privilege to comment on the SOUL trial NEJM #ACC2025 👉🏽 amazing that armementarium for treating T2DM & improving 🫀outcomes has expanded to oral GLP1RA 👉🏽 23% HF, 27% on SGLT2i - consistent results observed across subgroups (always looking to prevent HF!!!) 👉🏽didn’t meet sig

One of the most important trials at American College of Cardiology #ACC25 ! Compared fluid restriction to liberal approach in #HeartFailure. Why? This affects individuals w/HF EVERY DAY! ✨No benefit of Fluid Restriction ✨No HARM for liberal fluid intake ✨Improved QOL in liberal fluid intake

Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients w/ HF-CS compared to standard care. #ACC25 Read the journal scan to learn more: bit.ly/4c73BG4 #JACC JACC Journals

New NEJM #ACC25 The global impact of 5 cardiovascular risk factors (BP, cholesterol, obesity, diabetes, smoking) on life expectancy in men and women nejm.org/doi/full/10.10…

.Emer Joyce delivers insights on the Altshock-2 Randomised Clinical Trial #ACC25 #ESCTVOnTheRoad

Outstanding sci. statement from Sadiya Khan Don Lloyd-Jones et al on primary prev of HF. #PREVENTHF now enrolling, studying ASi+SGLT2i in >11k at risk participants, highlighting a new era for HF PREVENTION! clinicaltrials.gov/study/NCT06677… Muthu Vaduganathan scottdavidsolomon Maja Cikes Tor Biering-Sørensen, MD, MSc, MPH, PhD